TRC105

DRUG14 trials

Sponsors

National Cancer Institute (NCI), Tracon Pharmaceuticals Inc., University of Alabama at Birmingham, Cedars-Sinai Medical Center

Conditions

Advanced AngiosarcomaBreast CancerCancer of the UreterCarcinoma, HepatocellularChoriocarcinomaEpithelioid Trophoblastic TumorGestational Trophoblastic NeoplasiaGlioblastoma

Phase 1

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

CompletedNCT01090765

National Cancer Institute (NCI)Metastatic Castrate Resistant Prostate Cancer, Prostate Cancer

Start: 2010-02-23End: 2015-04-17Updated: 2018-05-22

Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

CompletedNCT01326481

Tracon Pharmaceuticals Inc.Metastatic Breast Cancer

Start: 2011-06-30End: 2014-12-31Updated: 2019-03-18

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

CompletedNCT02429843

University of Alabama at BirminghamLung Cancer

Start: 2015-11-02End: 2019-12-31Updated: 2021-06-28

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

CompletedNCT02520063

University of Alabama at BirminghamBreast Cancer

Start: 2015-02-01End: 2022-12-01Updated: 2026-02-06

Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC

CompletedNCT03780010

Tracon Pharmaceuticals Inc.Non Small Cell Lung Cancer

Start: 2015-09-30End: 2019-06-30Updated: 2019-10-28

Phase 2

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

CompletedNCT01328574

National Cancer Institute (NCI)Cancer of the Ureter, Neoplasm, Ureteral, Ureteral Neoplasms +2

Start: 2011-03-31End: 2014-11-30Updated: 2017-01-13

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

CompletedNCT01375569

National Cancer Institute (NCI)Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma

Start: 2011-06-22End: 2015-12-01Updated: 2017-07-28

A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma

CompletedNCT01564914

Tracon Pharmaceuticals Inc.Glioblastoma, Glioblastoma Multiforme

Start: 2012-05-31End: 2015-06-30Updated: 2019-06-12

TRC105 for Recurrent Glioblastoma

TerminatedNCT01778530

National Cancer Institute (NCI)Glioblastoma Multiforme

Start: 2012-12-31End: 2014-02-28Updated: 2015-10-07

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

CompletedNCT02396511

Tracon Pharmaceuticals Inc.Choriocarcinoma

Start: 2015-01-31End: 2017-12-31Updated: 2019-06-11

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

TerminatedNCT02664961

Tracon Pharmaceuticals Inc.Choriocarcinoma, Epithelioid Trophoblastic Tumor, Gestational Trophoblastic Neoplasia +1

Start: 2016-03-31End: 2018-11-30Updated: 2019-07-23

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

CompletedNCT03418324

Cedars-Sinai Medical CenterProstate Cancer

Start: 2018-03-05End: 2019-11-06Updated: 2020-12-30

Phase 3

Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma

CompletedNCT02979899

Tracon Pharmaceuticals Inc.Advanced Angiosarcoma

Start: 2017-02-13End: 2019-08-31Updated: 2020-05-12

Unknown Phase

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Tracon Pharmaceuticals Inc.Solid Tumors

Updated: 2021-02-15

Related Papers

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial.

2023-09-0811 citations

A randomized phase II study of apalutamide with or without carotuximab (ant-CD105) in metastatic, castration-resistant prostate cancer.

Journal of Clinical Oncology2023-06-014 citations

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

Breast Cancer Research and Treatment2023-02-034 citations

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma

JAMA Oncology2022-03-3145 citations

Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.

2019-08-08133 citations

An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)

Annals of Oncology2018-10-2465 citations

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.

2018-10-1118 citations

Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).

Journal of Clinical Oncology2018-05-201 citations

TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.

Journal of Clinical Oncology2018-05-201 citations

Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).

Journal of Clinical Oncology2017-05-207 citations

A phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma.

Journal of Clinical Oncology2016-05-2010 citations

TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib.

Journal of Clinical Oncology2014-01-201 citations